OOIR: Observatory of International Research

Papers

(The median citation count of Neurology-Neuroimmunology & Neuroinflammation is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	155
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	152
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	132
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	124
Elevated ITGAX/CD11c in CSF-Derived Extracellular Vesicles Reflects Disability Progression in Multiple Sclerosis	121
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	107
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	101
Antibody-Negative Autoimmune Encephalitis	89
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	88
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	84
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	74
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	74
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	73
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	69
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	68
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	66
Peripheral HLA-DR ^hi CD141 ⁺ Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis	63
Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway	62
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	61
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	61
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	59
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	57
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	51
Should We Measure CSF Complement Levels in Patients With MOGAD?	49
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	49

TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	48
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	48
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	48
Acute Paresthesia and Ataxia in a Child	47
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	46
Encephalitis and Myelitis in a Young Woman	46
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	45
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	45
Toward Precision Phenotyping of Multiple Sclerosis	45
Treatment With Erythropoietin for Patients With Optic Neuritis	45
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis	45
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	44
Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	44
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	44
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	43
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	43
Retinal Optical Coherence Tomography in Neuromyelitis Optica	43
Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice	43
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	43
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	43
Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders	43
Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls	42
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	42
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	42
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis	41
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	41
Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals	39
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy	38
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	38
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	38
Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity	37
Pediatric MOG-Ab–Associated Encephalitis	36
Acknowledgment to Reviewers	35
Absence of Systemic Oxidative Stress and Increased CSF Prostaglandin F2α in Progressive MS	35
A 42-Year-Old Woman With Rapidly Expanding White Matter Lesions	33
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease	33
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	33
“Will the Real Demyelinating Disorder Please Stand Up?”	33
Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy	32
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies	32
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	32
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models	31
Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients	31
B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis	31
Chronic Dengue Virus Encephalitis	31
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies	31
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient	30
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis	30
Neurologic Manifestations of Common Variable Immunodeficiency	30
Recovery From COVID-19 in Multiple Sclerosis	30

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab	30
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	30
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis	30
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	30
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis	29
Cryptococcal Meningitis Reported With Fingolimod Treatment	29
Clinical Characterization and Ancillary Tests in Susac Syndrome	29
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis	29
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis	29
Chronic Active Lesions and Larger Choroid Plexus Explain Cognition and Fatigue in Multiple Sclerosis	29
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis	29
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments	28
Distinguishing Transient From Persistent Brain Structural Changes in Pediatric Patients With Acute Disseminated Encephalomyelitis	28
Ten Years of Neurology ® Neuroimmunology & Neuroinflammation	28
Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis	28
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	27
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	27
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	27
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	26
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	26
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I)	26
PET Study of Microglial Activation in Kleine-Levin Syndrome	26
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	26
Progressive Encephalomyelopathy in an Older Man	26
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	26
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	25
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	25
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	25
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	25
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	25
Pediatric MOG-Ab–Associated Encephalitis	24
Neuropsychological Testing in Autoimmune Encephalitis	24
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	24
Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis	23
Progressive Myelitis in a 63-Year-Old Woman	23
Multiple Sclerosis in the Emergency Department	23
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	23
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	22
CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells	22
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	22
Cerebellar Ataxia With Anti-DNER Antibodies	22
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	22
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	22
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	22
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	22
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	22
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	22
Ravulizumab and Efgartigimod in Myasthenia Gravis	21
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	21
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	21
Antibody Investigations in 2,750 Children With Suspected Autoimmune Encephalitis	21
Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years	21
A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement	21
Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis	21
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders	21
Comparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With Onchocerca volvulus	20
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	20
Neuromyelitis Optica Spectrum Disorders in Africa	20
Single-Cell Multi-Omics Map of Cell Type–Specific Mechanistic Drivers of Multiple Sclerosis Lesions	20
Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade	20
Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation	20
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure	20
Inflammatory Activity After Diverse Fertility Treatments	20
Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies	20
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy	19
Human Leukocyte Antigen Association Study Reveals DRB104:02 Effects Additional to DRB107:01 in Anti-LGI1 Encephalitis	19
Autopsy Case of Meningoencephalomyelitis Associated With Glial Fibrillary Acidic Protein Antibody	19
Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli	19
Microglia as Central Protagonists in the Chronic Stress Response	19
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease	19
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	19
COVID-19 Severity in Multiple Sclerosis	19
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration	18
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis	18
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage	18
Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease	18
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis	18
MOG Antibody–Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use	18
Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling	18
Primary Angiitis of the CNS	18

Oral and Gut Dysbiosis in Migraine	18
Retrospective Pediatric Cohort Study Validates NEOS Score and Demonstrates Applicability in Children With Anti-NMDAR Encephalitis	18
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis	18
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	18
Immune Repertoire Profiling Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum Disorders	17
Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy	17
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	17
The Inner Nuclear Layer in Pediatric Multiple Sclerosis	17
Antibodies Against Glutamic Acid Decarboxylase 65 Are Locally Produced in the CSF and Arise During Affinity Maturation	17
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis	17
Cardiac Involvement in Neurosarcoidosis	17
Serum Autoantibody Titers and Neurofilament Light Chain Levels in CASPR2/LGI1 Encephalitis	17
Multiple Sclerosis	17
Intrathecal CD8 ⁺ CD20 ⁺ T Cells in Primary Progressive Multiple Sclerosis	17
Prolonged Corticosteroids Without Maintenance Immunotherapy for Treatment of Anti-LGI1 Encephalitis	17
Reemerging Infectious Diseases and Neuroimmunologic Complications	17
SARS-CoV-2 Vaccines and Multiple Sclerosis	17
Pregnancy and Infant Outcomes in Multiple Sclerosis	16
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies	16
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology	16
Modern Look at Transverse Myelitis and Inflammatory Myelopathy	16
Primary Angiitis of the CNS	16
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension	16
Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis	16
Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice	16
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	16
Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders	16
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis	16
CSF Parvalbumin Levels at Multiple Sclerosis Diagnosis Predict Future Worse Cognition, Physical Disability, Fatigue, and Gray Matter Damage	16
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	16
Real-Life Evaluation of the MOGAD Diagnostic Criteria	16
Acknowledgment to Reviewers	15
Neurology® Neuroimmunology & Neuroinflammation Acknowledgment to Reviewers	15
Electrolyte Imbalance in Anti LGI1 Encephalitis	15
CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis	15
Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates	15
Broad Analysis of Serum and Intrathecal Antimicrobial Antibodies in Multiple Sclerosis Underscores Unique Role of Epstein-Barr Virus	15
Clinical Characterization and Long-Term Outcome in Children and Adults With Anti-AMPA Receptor Encephalitis	15
Innate Immune Cell–Related Pathology in the Thalamus Signals a Risk for Disability Progression in Multiple Sclerosis	14
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	14
The Aryl Hydrocarbon Receptor–Dependent TGF-α/VEGF-B Ratio Correlates With Disease Subtype and Prognosis in Multiple Sclerosis	14
Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder	14
Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS	14
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis	14
Isolated Memory Loss in Anti-NMDAR Encephalitis	14
Evolution of Chronic Lesion Tissue in Relapsing-Remitting Patients With Multiple Sclerosis	14
Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Disease Responsive to Adalimumab and Prednisone	14
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series	14
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis	14
Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis	14
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	14
Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction	14
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	13
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis	13
Acknowledgment to Reviewers	13
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography	13
Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis	13
Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy	13
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab	13
Risk of Getting COVID-19 in People With Multiple Sclerosis	13
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis	12
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis	12
Vulnerability of Thalamic Nuclei at CSF Interface During the Entire Course of Multiple Sclerosis	12
Acute Optic Neuropathy in Older Adults	12
A New England COVID-19 Registry of Patients With CNS Demyelinating Disease	12
Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion	12
Therapies in Stiff-Person Syndrome	12
Pregnancy and Infant Outcomes in Women With Multiple Sclerosis Treated With Ocrelizumab	12
Alterations of Thymus-Derived Tregs in Multiple Sclerosis	12
Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis	12
Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis	12
Multiple Sclerosis, Disease-Modifying Therapies, and Infections	12
Relapsing White Matter Disease and Subclinical Optic Neuropathy	12
Late-Onset Anti-GABA _B Receptor Encephalitis	12
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD	12
Post-COVID Small Fiber Neuropathy, Implications of Innate Immunity, and Challenges on IVIG Therapy	11
Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion	11
Serum Contactin-1 in CIDP	11
White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity	11
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	11
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II)	11
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis	11
GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder	11
Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody–Positive Stiff-Person Syndrome	11
Analysis of Macrophages and Peptidergic Fibers in the Skin of Patients With Painful Diabetic Polyneuropathy	11
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis	11
Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases	10
Corrections to Preprint Server Information	10
Trajectories of Inflammatory Markers and Post–COVID-19 Cognitive Symptoms	10
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	10
Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey	10
Pachymeningitis in Biopsy-Proven Sarcoidosis	10
CNS Inflammation as the First Sign of Complement Factor I Deficiency	10
Structural Changes of Cutaneous Immune Cells in Patients With Type 1 Diabetes and Their Relationship With Diabetic Polyneuropathy	10
Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature	10